ArticleChemico-biological interactions2010
Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system.
Article in Chemico-biological interactions, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Butyrylcholinesterase-Loaded Liposomes and Polymersomes: Catalytic Parameters for Three Types of Substrates.International journal of molecular sciences · 2025Article
- Recent Development of Nanoparticle Platforms for Organophosphate Nerve Agent Detoxification.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- Advancements in bioscavenger mediated detoxification of organophosphorus poisoning.Toxicology research · 2024Review
- Strategies for enhanced bioavailability of oxime reactivators in the central nervous system.Archives of toxicology · 2023Review
- Review of Possible Therapies in Treatment of Novichoks Poisoning and HAZMAT/CBRNE Approaches: State of the Art.Journal of clinical medicine · 2023Review
- Perspectives on Nanodelivery to the Brain: Prerequisites for Successful Brain Treatment.Molecular pharmaceutics · 2020Review
- Signature Ions in MS/MS Spectra for Dansyl-Aminohexyl-QQIV Adducts on Lysine.Molecules (Basel, Switzerland) · 2020Article
- Cholinesterases and the fine line between poison and remedy.Biochemical pharmacology · 2018Review
- GEMALS: A promising therapy for amyotrophic lateral sclerosis.Experimental and therapeutic medicine · 2018Article
- Enzymatic detoxification of organophosphorus pesticides and related toxicants.Journal of pesticide science · 2018Article
- Article
- Synthesis and study on activity in vitro of the high purity human butyrylcholinesterase conjugated with gold nanoparticles.Doklady. Biochemistry and biophysics · 2016Article
- SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Agile delivery of protein therapeutics to CNS.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.Biomaterials · 2013Article
- Advances in toxicology and medical treatment of chemical warfare nerve agents.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2012Article
- Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Recent advances in the treatment of organophosphorous poisonings.Iranian journal of medical sciences · 2012Article
- In vivo methods to study uptake of nanoparticles into the brain.Pharmaceutical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Butyrylcholinesterase (BChE) is an efficient bioscavenger of highly toxic organophosphorus poisons and nerve agents. However, BChE administered into the periphery does not provide significant protection of the central nervous system (CNS) due to rejection by the blood-brain barrier. In this study, we evaluated the feasibility of delivering BChE to the CNS by packing it into a block ionomer complex of nanoscale size with a cationic poly(l-lysine)-graft-poly(ethylene oxide) (PLL-g-PEO) copolymer. The multimolecular structure of BChE/PLL-g-PEO complexes was further reinforced by formation of cross-links between the polymer chains. The resulting cross-linked complexes were stable against dilution without significant loss of BChE enzymatic activity. In some cases the BChE was labeled with fluorescent IRDye 800CW before it was incorporated into nanoparticles. BChE/PLL-g-PEO complexes were injected into mice intramuscularly and intravenously. In vivo imaging showed incorporation of the fluorescently labeled BChE in brain. Activity assays showed that BChE remained active in the brain at 72-h post-injection. It was concluded that nanocomplexes can deliver the 340 kDa BChE tetramer to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.